CPC-126 Second-Line Chemotherapy with Nab-Paclitaxel in Patients with Pancreas Cancer

Abstract

Background Pancreatic cancer is one of the most deadly forms of cancer. Standard treatment in metastatic disease is the quemotherapy with gemcitabine, but there is not a standard therapy for gemcitabine-refractory patients. Purpose Assess the off-label efficacy of nab-paclitaxel, in patients who progressed on gemcitabine-based therapy, in our hospital. Materials and Methods Observational retrospective study of pancreatic cancer patients treated with nab-paclitaxel who progressed on gemcitabine-based therapy from June 2011 to April 2012. Data were collected from clinical history, Oncofarm® and Omega3MIL® programmes. We determined: Progression free survival (PFS) and Overall Survival (OS). 12 patients (100% male) were treated with nab-paclitaxel. Eleven of them presented metastatic desease. The patients were treated with two therapies: nab-paclitaxel 100 mg/m2 (1.8,15/28d). 5 patients received this treatment. Median age was 79.4 years (sd = 4.2 years) Gemcitabine 1000 mg/m2 plus nab-paclitaxel 100 mg/m2 (1.8,15/28d): 7 patients received this treatment; Median age was 65.5 years (sd = 6.9 years). Results Median PFS was 2,8 months (95% CI, 1.5 to 4.1 months) with single agent, and 5.3 months (95% CI, 4.0 to 6.5 months) with gemcitabine plus nab-paclitaxel. The PFS in the study was 20% and 83% respectively. The OS couldn’t be determine in the nab-paclitaxel group, because there wasn’t any event during the study period. The OS with gemcitabine plus nab-paclitaxel was 66.7%. Conclusions It showed better clinical outcomes in the gemcitabine plus nab-paclitaxel group in PFS. The nab-paclitaxel can be an effective second-line chemotherapy in gemcitabine resistant patients. No conflict of interest.